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Creating Flavin Reductase Variants with Thermostable and
Solvent-Tolerant Properties by Rational-Design
Engineering
Somchart Maenpuen,[a] Vinutsada Pongsupasa,[b] Wiranee Pensook,[a] Piyanuch Anuwan,[b]
Napatsorn Kraivisitkul,[c] Chatchadaporn Pinthong,[d] Jittima Phonbuppha,[b]
Thikumporn Luanloet,[e] Hein J. Wijma,[f] Marco W. Fraaije,[f] Narin Lawan,[g]
Pimchai Chaiyen,[b, e] and Thanyaporn Wongnate*[b]
Introduction
Enzymes play a major role in biotechnology and serve as at-
tractive, efficient, selective, and sustainable biocatalysts for
processes involved in the production of pharmaceuticals, fine
chemicals, and biofuels.[1, 2] However, the issue of protein insta-
bility poses a fundamental challenge to the use of enzymes for
practical-scale syntheses and chemical manufacturing, because
these often require harsh reaction conditions such as elevated
temperatures and exposure to organic solvents.[1] Because of
these limitations, stabilization of proteins against thermal and
chemical denaturation has been a longstanding goal in
enzyme engineering. As well as providing improved robustness
under harsh operational conditions, increasing the thermosta-
bility of a protein can also enhance its evolvability for various
applications.[3]
A variety of methods, including immobilization,[4, 5] medium
engineering,[6] and protein engineering,[7] have been used to
improve the thermodynamic and kinetic stability of enzymes.
In protein engineering, directed evolution and semirational or
rational design are three general methods employed to obtain
thermostable variants of a target enzyme.[6] A number of stud-
ies have shown that directed evolution can enhance the per-
formance of enzymes at elevated temperatures.[8, 9] However,
this technique requires screening of large numbers of clones
(e.g. >10 000); this is laborious and time-consuming and typi-
cally requires several rounds of mutagenesis and screening to
We have employed computational approaches—FireProt and
FRESCO—to predict thermostable variants of the reductase
component (C1) of (4-hydroxyphenyl)acetate 3-hydroxylase.
With the additional aid of experimental results, two C1 variants,
A166L and A58P, were identified as thermotolerant enzymes,
with thermostability improvements of 2.6–5.6 8C and increased
catalytic efficiency of 2- to 3.5-fold. After heat treatment at
45 8C, both of the thermostable C1 variants remain active and
generate reduced flavin mononucleotide (FMNH@) for reactions
catalyzed by bacterial luciferase and by the monooxygenase C2
more efficiently than the wild type (WT). In addition to thermo-
tolerance, the A166L and A58P variants also exhibited solvent
tolerance. Molecular dynamics (MD) simulations (6 ns) at 300–
500 K indicated that mutation of A166 to L and of A58 to P
resulted in structural changes with increased stabilization of
hydrophobic interactions, and thus in improved thermostabili-
ty. Our findings demonstrated that improvements in the ther-
mostability of C1 enzyme can lead to broad-spectrum uses of
C1 as a redox biocatalyst for future industrial applications.
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obtain variants with significantly increased thermostability
(DTm>5–10 8C).
[10] The B factor iterative test (B-FIT) has been
shown to be a promising method for protein engineering. This
methodology aims to rigidify the most flexible residues in a
protein and has been employed as a semirational strategy to
improve the thermostabilities of several enzymes.[11–15] Never-
theless, thousands of clones must be constructed for screen-
ing, and many stabilized mutations are missed if the targeted
residues with high B factors are not located in the most critical
regions for stability.[16] Computational design has become feasi-
ble as a rational-design method to improve thermostability.[17]
This technique provides reasonable predictive accuracy and
reduces the need for laborious experimental screening. Several
methods aim to optimize native state interactions, variously
through improving core packing[18–20] or fragment contacts,[21]
or by performing combined structure- and phylogeny-guided
energy optimization,[22, 23] surface-charge optimization,[24, 25] and
rigidification.[16, 26] Many computational approaches directed
towards predicting the stabilizing effects of mutations, such as
the FoldX[27] and Rosetta[28] algorithms, have been developed.
The reductase component (C1) of a two-component (4-hy-
droxyphenyl)acetate (HPA) 3-hydroxylase (HPAH) from Acineto-
bacter baumannii is an NADH:flavin mononucleotide (FMN) oxi-
doreductase that catalyzes the reduction of FMN by NADH to
generate reduced FMN (FMNH@) for its monooxygenase coun-
terpart (C2) to hydroxylate the HPA substrate for the synthesis
of (3,4-dihydroxyphenyl)acetate (DHPA) in the presence of mo-
lecular oxygen (Scheme 1).[29–32] In the case of the two-compo-
nent flavin-dependent monooxygenases, in general, the re-
duced flavin generated by a flavin reductase must be trans-
ferred to a corresponding monooxygenase to complete the
hydroxylation reaction. Therefore, key biological processes
such as catabolism, detoxification, biosynthesis, and light emis-
sion often involve coupled reductase- and monooxygenase-
catalyzed reactions.[32, 33, 35–40]
C1 is unique among the flavin reductases in that the HPA
substrate can stimulate the rates both of FMN reduction and
of FMNH@ release.[30, 31, 33, 34] X-ray structures of FMN-bound C1
have been solved at 2.2 a (PDB ID: 5ZYR; Oonanant et al. , un-
published results) and 2.9 a (PDB ID: 5ZC2).[34] The structural
analyses indicated that C1 exists as a homodimer and that each
subunit consists of two domains: N- and C-terminal domains
(Figure S1). The N-terminal domain (residues 1–169) is a flavin
reductase domain that contains tightly bound FMN, whereas
the C-terminal domain (residues 190–315) is predicted to be a
MarR domain, typically found as a transcription factor. These
two domains are linked by a flexible loop (residues 170–
189).[33, 34] Thanks to its redox reaction generating FMNH@ , C1
has been applied in the enzymatic cascade reactions of the
bacterial luciferase (luxAB) from Vibrio campbellii[45] and mono-
oxygenase (C2)
[41, 42] to produce a bioluminescence signal as a
promising eukaryote gene reporter or to synthesize trihydroxy-
phenolic acids such as 3,4,5-trihydroxycinnamic acid (3,4,5-
THCA) and (3,4,5-trihydroxyphenyl)acetic acid (3,4,5-THPA),
which are strong antioxidants. However, these reactions were
performed only at room temperature, because C1 is rather un-
stable at higher temperatures. Therefore, improvement of the
thermostability of C1 is requisite for broad-spectrum uses in
the reactions of other two-component flavin-dependent mono-
oxygenases that effect regio- and stereospecific oxygen inser-
tions to produce pharmaceutical ingredients and fine chemi-
cals in industrial applications.[46–49]
In this work we have used in silico approaches—FireProt
and FRESCO (framework for rapid enzyme stabilization by com-
putational libraries) programs—to help predict and engineer
C1 variants with greater thermostability. The computational cal-
culations using two protein engineering tools (FoldX and Ro-
setta), together with energy- and evolution-based calculations,
suggested a library of 30 stable C1 variants. With our screening
methods and experimental approaches, only two stable C1 var-
iants—A166L and A58P—were candidate variants showing im-
provements in thermostability, with 3–6 8C higher melting tem-
peratures (Tm), and increased catalytic efficiency relative to the
WT C1 enzyme. On heating at 45 8C, both C1 variants were ther-
motolerant, with their residual activities retaining about half of
their initial values, and still more active than the WT in gener-
ating FMNH@ for supply to the reactions catalyzed by luxAB
and by C2. From the lower energy barriers it was inferred that
thermostable C1 variants generate FMNH
@ more rapidly than
the WT. In addition to thermotolerance, the A166L and A58P
variants also exhibited solvent tolerance. The results obtained
from molecular dynamics (MD) simulations suggested that mu-
tations of A166 to L and of A58 to P resulted in increased ther-
mostability due to hydrophobic–hydrocarbon interactions be-
tween L166 and L168 and between R201 and Q204 and aro-
matic–hydrocarbon interactions between P58 and F19 and I14.
Our results demonstrate that the use of computational calcula-
tions helps create stable C1 variants with improved thermosta-
bility and that the rationally designed engineered enzymes
also showed increased catalytic efficiency.
Results and Discussion
Use of in silico approaches to predict stable C1 variants
We used two computational calculation programs—Fire-
Prot[23, 50] and FRESCO[16, 51]—to predict stable C1 variants. The X-
ray structure of the WT C1 (PDB ID: 5ZYR) was processed with
the FireProt program to predict stable variants through a com-
bination of energy- and evolution-based computational ap-
proaches.[50] FireProt uses two protein engineering tools, FoldX
and Rosetta, to compute the differences in folding free energy
Scheme 1. The C1-catalyzed reaction that generates FMNH
@ for monooxyge-
nase-catalyzed reactions. The NADH-regenerating system might be, for ex-
ample, glucose/glucose dehydrogenase, glucose 6-phosphate/glucose 6-
phosphate dehydrogenase,[41, 42] or formate/formate dehydrogenase.[43, 44] The
monooxygenases might be, for example, C2 or bacterial luciferase.




change (DDGfold) of the WT (DGfold,WT) and variant (DGfold,variant)
so as to evaluate the folding stability of each variant. DDGfold
values of less than @1 kcal mol@1 were used to identify the
stable variants.[50, 52] From the DDGfold values, 15 single-point
mutations were predicted as stable candidate variants. Twelve
of the stable variants (A18M, N132M, S155P, V167P, A180Y,
G186F, V200W, T218W, S219A, Q239M, E248D, and N307Y)
were obtained from the energy-based approach, whereas an
additional three stable variants (A58P, N106G, and T298S) were
obtained from the evolution-based approach (Table S1).
In addition to FireProt, computational prediction by FRESCO,
employing energy-based calculation by use of the FoldX and
Rosetta tools together with prediction of disulfide bond forma-
tion,[16] provided another 15 variants : E10N, E10R, E10Q, A88R,
A166D, A166M, A166L, A202W, A221M, A232K, A232Q, A232N,
A232H, A243N, and A243G. It should be noted that stable C1
variants featuring mutations of surface hydrophilic amino acids
to hydrophobic side chains should be omitted due to concerns
relating to low protein solubility.[51] Altogether, a library of 30
stable mutated C1 variants was identified.
Thermal screening of the thermostable C1 variants
Expression constructs harboring each C1 variant were overex-
pressed in Escherichia coli under optimized conditions as de-
scribed in the Experimental Section. After cell disruption and
debris separation by centrifugation, the crude extracts contain-
ing each C1 variant were heated at 45 8C for 10 min and the
clear supernatants were assayed for NADH oxidation activity in
the presence of HPA. Reaction progress was monitored for
absorbance change at 340 nm. The reaction slope and specific
activity for each variant were determined. The specific activities
of only ten stable C1 variants—E10Q, A18M, A58P, N106G,
A166L, V200W, A202W, A232K, A232N, and S219A—were
higher than or comparable with that of the WT. By this screen-
ing method, we were able to narrow down the number of
stable C1 variants showing improved thermostability.
In order to verify the selection of C1 variants possessing im-
proved thermostability, thermal denaturation of the purified C1
variants compared to that of the WT was investigated. All ten
selected C1 variants, as well as the WT, were purified to homo-
geneity by precipitation methods and column chromatography
as described in the Experimental Section and the purity of
each C1 variant with the subunit molecular weight (MW) of
35 kDa was assessed by 12 % (w/v) SDS-PAGE (Figure S2). Each
of the purified C1 variants was examined with regard to ther-
mal denaturation by employment of the bound FMN fluores-
cence-based thermal shift assay by using a real-time poly-
merase chain reaction (PCR) apparatus with a gradient temper-
ature increase mode.[53, 54] The Tm values of C1 variants and of
the WT were determined from the melting curves and are sum-
marized in Table 1. To verify the measured Tm values, two inde-
pendent batch preparations of each C1 variant were prepared
and multiple Tm measurements were performed. The results in
Table 1 indicate that, in relation to that of the WT, only three
C1 variants—A58P, A202W, and A166L—showed significantly
higher DTm values (2.6–5.6 8C), thus suggesting that they were
highly thermostable, whereas the only slightly increased DTm
values (0.3–1.8 8C) of the other variants (E10Q, A232K, A18M,
S219A, N106G, and A232N) indicated only moderate thermal
stability. On the other hand, the Tm value of the variant V200W
was much less than that of the WT, thus indicating significantly
lower thermostability. These data demonstrated that prediction
of mutation sites with the aid of the computational algorithms
of the FireProt and FRESCO programs can provide rationally
designed C1 variants with improved thermostability.
Comparison of the NADH oxidation kinetics of selected
thermostable C1 variants relative to the WT
The results in the above section showed that only three candi-
date C1 variants—A58P, A202W, and A166L—showed signifi-
cantly higher thermostability (>2.0 8C) than the WT. We then
investigated the kinetics of NADH oxidation by the bound
FMN component in each thermostable C1 variant at 25 8C in
the presence and in the absence of HPA and compared them
with those of the WT. The kinetic constants, kcat, Km, and kcat/Km,
for each thermostable C1 variant were determined and com-
pared with those of the WT. As shown in Table 2, the kcat
values for the reaction catalyzed by the A166L variant in the
presence and in the absence of HPA were about 2–3.5 times
higher than those of the WT, thus showing that the A166L var-
iant catalyzes the reaction more effectively than the WT. Con-
currently, the reaction catalyzed by the A58P variant showed
kcat values similar to those of the WT. On comparison of the
kcat/Km values, which represent the catalytic efficiency of NADH
Table 1. Melting temperature (Tm) values of C1 variants, relative to the
WT.
C1 enzyme Tm [8C]
[a] DTm [8C]
[b] C1 enzyme Tm [8C]
[a] DTm [8C]
[b]
WT 50.7:0.5 0.0 A166L 56.3:1.2 5.6
A202W 55.5:0.8 4.8 A58P 53.3:0.8 2.6
A232N 52.5:0.8 1.8 N106G 52.3:0.8 1.6
S219A 52.0:0.0 1.3 A18M 51.5:0.5 0.8
A232K 51.2:0.4 0.5 E10Q 51.0:0.6 0.3
V200W 47.7:0.5 @3.0
[a] The S.D. values were calculated from the Tm values obtained from two
independent batch preparations and multiple Tm measurements of each
C1 variant. [b] The DTm values were calculated by subtraction of the Tm
value of the WT from that of each variant.
Table 2. Comparison of the catalytic efficiency of thermostable C1 var-
iants in relation to the WT.
C1 enzyme @HPA[a] + HPA[a]
kcat Km kcat/Km kcat Km kcat/Km
[s@1] [mm] [mm@1 s@1] [s@1] [mm] [mm@1 s@1]
WT 13.3 9.1:1.6 1.5 164.9 65.4:5.7 2.5
A166L 46.0 32.8:9.9 1.4 345.3 131.8:10.5 2.6
A202W 0.1 10.7:5.5 0.0093 0.4 0.4:0.1 1.0
A58P 17.0 5.8:0.9 2.9 181.0 30.9:5.1 5.8
[a] The reaction assays were performed at 25 8C.




oxidation activity of C1, the A58P variant showed kcat/Km values
about twice those of the WT in the presence and in the ab-
sence of HPA, whereas the A166L variant showed values com-
parable to those of the WT. The kinetic data suggested that
both the A166L and the A58P variants were potentially more
suitable candidates than the WT for biocatalysis applications
because they can generate the FMNH@ much more rapidly. In
contrast to those catalyzed by the A166L and A58P variants,
the reactions catalyzed by the A202W variant in the presence
and in the absence of HPA showed very low kcat and kcat/Km
values, thus implying that this variant has a much lower turn-
over and catalytic efficiency for NADH oxidation, and thus
shows decelerated generation of the FMNH@ .
Thermotolerance of selected thermostable C1 variants
The work described in the previous sections suggested that
only the A58P and the A166L C1 variants exhibited reasonable
improvements in Tm and catalytic efficiency relative to the WT.
In order to investigate further whether the two selected ther-
mostable C1 variants were indeed thermotolerant, time-course
heat treatment of the C1 variants was performed and the resid-
ual NADH oxidation activity of each C1 variant in the presence
or in the absence of HPA was measured and compared with
that of the WT. Because the Tm values of the WT and of the
A58P and A166L enzymes were 50.7, 53.3, and 56.3 8C, respec-
tively (Table 1), an incubation temperature of 45 8C was
chosen; at this temperature each of the C1 variants should still
be active for a certain period during incubation. After incuba-
tion at 45 8C for various time periods (0–180 min), the data ob-
tained from the reaction in the absence of HPA (Figure 1 A) in-
dicated that only the A58P variant showed a reasonable resid-
ual activity, of about 33 % of its initial activity, after incubation
for 180 min. Meanwhile, the residual activities both of the
A166L variant and of the WT were decreased drastically, retain-
ing only about 7 % of their initial activity after only 5 to 10 min
incubation. In contrast with the reaction in the absence of
HPA, the residual activities in the presence of HPA for both C1
variants showed retention of as much as 50 % of their initial
activity after 180 min incubation, whereas the WT enzyme re-
tained only about 15 % of its initial activity (Figure 1 B).
All of these results demonstrated that, in the presence of
HPA, both A58P and A166L C1 variants were thermotolerant
and feasible candidates for further uses in biocatalysis applica-
tions at high temperature (see later results). Furthermore, the
results indicated that the binding of HPA to each C1 variant
can enhance thermotolerance. This could be explained in
terms of the influence of a substantial conformational change
in the C1 variant upon HPA binding at the C-terminal
domain.[34] Similarly enhanced structural stabilization upon
ligand binding has also been observed in the cases of many
other enzymes.[55–57] The data obtained also verified that the
use of FireProt and FRESCO programs can aid rational design
of C1 variants with improved thermostability.
Generation of the reduced FMN by thermostable C1 variants
has a lower barrier energy than in the case of the WT
On the basis of the steady-state kinetics of NADH oxidation at
25 8C, it had been shown that the overall catalysis by both the
A58P and the A166L C1 variants was faster than that by the
WT (Table 2). Hence, we hypothesized that the C1-bound FMN
reduction by NADH could be altered through temperature
changes. The transient kinetics of C1-bound FMN reduction by
NADH under anaerobic conditions at various temperatures
were studied by stopped-flow spectrophotometry with moni-
toring at 458 nm. The kinetic traces upon changes in tempera-
ture were analyzed for each C1 enzyme reaction (Figure S3).
The results indicated that, at all temperatures employed in all
C1 enzyme reactions, the bound FMN reduction kinetics were
biphasic, with both fast and slow flavin reduction. This is simi-
lar to the previous report.[31] In this case, only the apparent
rate constants of the fast reduction kinetics (kred) were deter-
mined, because the amplitude change at 458 nm mainly ac-
counted for about 80 % of overall flavin reduction (Figure S3).
The Eyring plots of kred versus different temperatures were ana-
lyzed for each C1 variant (Figure 2). The curve plot showed that
the kred values for reduction in the presence of each C1 variant
increased exponentially as the temperature was increased to
50 8C (Figure 2 A).
To obtain the enthalpy of activation (DH*) of each C1 reac-
tion, the linear form of the Eyring plot was analyzed (Fig-
ure 2 B). The DH* values for the A58P and the A166L variants
were calculated to be 13.2 and 12.7 kcal mol@1, respectively,
and hence 0.5 and 1.0 kcal mol@1 lower, respectively, than that
of the WT (13.7 kcal mol@1). The data showed that the energy
barriers for generation of the reduced flavin in the presence of
the thermostable C1 variants were lower than that of the WT,
thus implying that the selected thermostable C1 variants can
Figure 1. Time-course thermotolerance of C1 variants, relative to the WT, at
45 8C. The relative residual activity of each C1 variant (A58P, *, and A166L, &)
was measured and compared to that of the WT (~) in A) the absence, or
B) the presence of HPA at 45 8C. Error bars represent S.D.s.




produce the reduced flavin more rapidly, which is suitable for
biocatalysis applications (see next results).
Evidence showing that thermostable C1 variants are effec-
tive biocatalysts for supplying the reduced flavin for bio-
luminescence and for bioactive compound synthesis at
high temperatures
Previous studies had demonstrated that the reaction catalyzed
by the C1 WT can supply the reduced flavin for the reactions of
flavin-dependent monooxygenases such as the HPAH oxygen-
ase component C2 for a one-pot synthesis of 3,4,5-THCA
[41, 42]
or of the bacterial luciferase luxAB for generation of bio-
luminescence.[45, 58] Therefore, to investigate whether the two
selected thermostable C1 variants were more effective than the
WT in supplying the reduced flavin for the C2- and luxAB-cata-
lyzed reactions, the C1 variants and WT enzymes were subject-
ed to preheating at 45 and 54 8C prior to the reaction. It
should be noted that only the C1 enzymes heated to 45 8C
were used in the C2-catalyzed reaction (see details in Experi-
mental Section).
The results shown in Figure 3 A illustrated that the luxAB-cat-
alyzed reaction in the presence of the C1 variants heated to
45 8C showed a bioluminescence signal about half that of the
reaction in the presence of unheated C1 WT, whereas the biolu-
minescence signal obtained from the reaction in the presence
of the heated C1 WT showed a signal only about 16 % of that
performed in the presence of unheated C1 WT. With the C1
enzymes heated at 54 8C, the bioluminescence signal obtained
from a luxAB-catalyzed reaction in the presence of the heated
A166L variant was still half that of the reaction in the presence
of unheated C1 WT, whereas in the reaction in the presence of
the heated A58P variant it was reduced to 16 %. In contrast, no
significant bioluminescence signal was detected in the reaction
in the presence of heated C1 WT. The data indicated that the
two thermostable C1 variants are thermotolerant and can be
used as efficient means of FMNH@ generation in luciferase-
based eukaryotic gene reporter assays at physiological temper-
ature (37 8C) and even at higher temperatures.[45, 58]
For the synthesis of 3,4,5-THCA—a bioactive compound pos-
sessing a variety of biological activities including antibacteri-
al,[59] anti-inflammatory,[60–63] and antivenom[64]—with the aid of
the C2-catalyzed reaction, the results in Figure 3 B showed that
the rates of 3,4,5-THCA product formation in the reactions in-
volving both heated C1 variants (0.28 and 0.30 mm min
@1 for
the A58P and the A166L variant, respectively) were each about
twice as fast as than that achieved with the heated C1 WT
(0.18 mm min@1). The results showed that the increased rate of
3,4,5-THCA product formation in the C2-catalyzed reaction in
the presence of both C1 variants was due to their thermotoler-
ant property that promotes their abilities to generate the re-
duced flavin more rapidly. The data suggested that both ther-
mostable C1 variants are promising efficient biocatalysts for
providing the reduced flavin for the synthesis of other valuable
fine chemicals through catalysis by flavin-dependent monooxy-
genases. Altogether, the results obtained from both the luxAB-
and the C2-catalyzed reactions demonstrate that improvement
of thermostability can enhance C1 enzymes as robust biocata-
lysts for biotechnology applications.
Figure 2. Effects of temperature on generation of the reduced flavin through
the action of thermostable C1 variants relative to the WT. A) Exponential
forms of Eyring plots of the apparent rate constants of the fast reduction
kinetics (kred) versus various temperatures (15 to 50 8C) for A58P (*) and
A166L (&), in comparison with WT (~). B) Linear forms of Eyring plots of kred/
T versus 1/T. The enthalpies of activation (DH*) of the A58P and A166L var-
iants were calculated to be 13.2 and 12.7 kcal mol@1, respectively, 0.5 and
1.0 kcal mol@1 lower, respectively, than that of the WT (13.7 kcal mol@1). Error
bars represent S.D.s.
Figure 3. The use of thermostable C1 variants for A) FMNH
@ generation for
bioluminescence, and B) production of 3,4,5-THCA. A) The % relative light in-
tensities obtained from luxAB-catalyzed reactions in the presence of C1 WT
(black) and the A58P (blue) and A166L (red) variants heated at 45 or 54 8C
compared to that obtained from the reaction in the presence of unheated
C1 WT (gray). B) 3,4,5-THCA produced over time in the multiple turnover
reactions catalyzed by the C2 Y398S mutant in the presence of the C1 WT
(black line with triangles) and the A58P (blue line with circles) and A166L
(red line with squares) variants heated at 45 8C to produce FMNH@ . Error
bars represent S.D.s.




Thermostable C1 variants exhibit solvent tolerance
In order to examine whether thermostable C1 variants show
solvent tolerance, the NADH oxidation activities of the solvent-
treated thermostable C1 variants and of the WT were measured
and compared. Each C1 enzyme was immersed in organic sol-
vents—DMSO, MeOH, and EtOH—at different concentrations
at 25 8C prior to the NADH oxidation activity assay (see details
in Experimental Section). The results, given in Figure 4, show
that at 10 % (v/v) of every solvent used for treating all of the
C1 enzymes, the relative NADH oxidation activity of all treated
C1 enzymes was unchanged in relation to that of each untreat-
ed C1. When the solvent concentration was increased to 30 %
(v/v), the relative activity of both thermostable C1 variants
treated with DMSO were slightly reduced (5 % reduction),
whereas the C1 WT activity was reduced to 83 % (Figure 4 A). In
the case of MeOH-treated C1 (Figure 4 B), only the relative ac-
tivity of the A166L variant was found to be unchanged, where-
as that of the A58P variant was reduced to 70 %, and that of
the WT was drastically decreased (70 % reduction). In the case
of EtOH-treated C1 (Figure 4 C), it was found that only about
30 % activity of the A166L variant was detected, whereas the
activities of the A58P variant and the WT were almost abolish-
ed. The results indicated that the A166L variant is tolerant, to
some degree, to all solvents used, at concentrations up to
30 % (v/v). The ability of the A166L variant to resist all solvents
could be due to the mutation of A166 to L resulting in an
alteration of the overall conformation of the C1 variant, thus
preventing solvent accessibility. These data indicated that the
A166L C1 variant might have potential for further development
as a robust redox biocatalyst for solvent-dependent synthesis
of fine chemicals.
Use of MD simulations to explain the thermostability
improvement in C1 variants
As demonstrated in the preceding sections, our results re-
vealed that A166L and A58P C1 variants are thermostable and
solvent-tolerant enzymes that could effectively generate the
reduced flavin for the reactions catalyzed by luxAB and by C2.
To explain why single-point mutations of A166 to L and of A58
to P can improve the thermostability of the C1 enzyme, we
performed MD simulations on the two thermostable C1 var-
iants for comparison with the WT so as to investigate the plau-
sible roles of these mutated residues that might help stabilize
the protein structure and be involved in flavin reactivity. MD
was used to investigate the possible interactions engaged in
by A166 or A58 and nearby residues that might help stabilize
the protein structure under elevated temperatures. Analysis of
the C1 structure (PDB ID: 5ZYR) shows that A166 is near L168,
R201, and Q204 (Figure 5 and S4) and that A58 is near I14 and
F19 (Figure 6 and S5). Therefore, the distances between the Ca
atoms of the residue pairs (A166/L166 and L168, A166/L166
and R201, A166/L166 and Q204, A58/P58 and I14, and A58/P58
and F19) were monitored over MD simulations of 6 ns at 300–
500 K.
The results obtained from the MD simulations showed that
increasing temperature caused all distances to increase in the
case of the WT (Figures 5, 6, S4, and S5). In the cases of the
A166L and A58P variants, however, all five distances between
Ca of the residue pairs were stable and did not increase with
temperature (Figures 5, 6, S4, and S5). This result indicated that
these variants were more thermostable than the WT. The ther-
mostability of the A166L variant was improved due to hydro-
phobic–hydrocarbon interactions between L166 and L168 and
between R201 and Q204 (Figures 5 and S4). Mutation of amino
acid residues with a shorter aliphatic side chain (Ala) to ones
with a longer, bulkier side chain (Leu) on the surface of a chain
region is more likely to generate beneficial mutants due to the
formation of strong linkages, maximizing contacts with the
inner chain, and minimizing entropy effects. The mutation
A166L evidently increased hydrophobic interactions at the in-
terface between the subunits, and this stabilized the quaterna-
ry structure at higher temperatures without decreasing the
specific activity. In the case of the A58P variant, the thermosta-
bility improvement was due to aromatic–hydrocarbon interac-
tions between P58 and F19 and I14 (Figures 6 and S5).
Conclusions
This study used in silico approaches to rationally design var-
iants of the reductase component (C1) of (4-hydroxyphenyl)a-
cetate 3-hydroxylase (HPAH) with improved thermostability. Ac-
cording to the employed experimental approaches, two C1 var-
iants—A166L and A58P—were found to possess greater ther-
mostability with increased Tm values and greater catalytic effi-
ciency in relation to the WT enzyme. Both thermostable C1
variants remained active after preheating at 45 8C and were
Figure 4. Relative solvent-tolerant NADH oxidation activity of thermostable C1 variants compared to the WT. Relative activity of C1 WT (black), A58P (blue),
and A166L (red) pretreated with different concentrations (0, 10, and 30 %, v/v) of A) DMSO, B) MeOH, and C) EtOH. Error bars represent S.D.s.




able to generate the reduced flavin (FMNH@) for the reactions
catalyzed by bacterial luciferase (luxAB) and by monooxygena-
se C2. The energy barriers for FMNH
@ generation in the cases
of both thermostable C1 variants were lower than those in that
of the WT enzyme, thus implying that both variants could pro-
duce FMNH@ more rapidly than the WT. In addition to thermo-
stabilty, both C1 variants also exhibited solvent tolerance. This
was especially evident with the A166L variant, which remained
active after pretreatment with 30 % (v/v) DMSO, methanol, and
ethanol. MD simulations at a high temperature indicated that
the single-point mutations of A166 to L and of A58 to P could
maintain the distances around those residues through hydro-
phobic– and aromatic–hydrocarbon interactions, respectively,
resulting in thermostability improvements in both C1 variants.
Experimental Section
Chemicals : All chemicals and reagents used were of analytical
grade and commercially available. PCR primers were synthesized
by HAP Oligo Synthesis (Bio Basic, Inc. , USA). Concentrations of the
following compounds were calculated on the basis of known ex-
tinction coefficients at pH 7.0: NADH has e340 = 6.22 mm
@1 cm@1,
HPA has e277 = 1.55 mm
@1 cm@1, FMN has e446 = 12.2 mm
@1 cm@1, C1
has e458 = 12.8 mm
@1 cm@1, and C2 has e280 = 56.7 mm
@1 cm@1.[30–33] p-
Coumaric acid (CMA) has e285 = 16.92 mm
@1 cm@1, caffeic acid (CFA)
has e312 = 9.42 mm
@1 cm@1, and 3,4,5-THCA has e300 =
12.7 mm@1 cm@1.[42]
In silico methods for design of C1 variants : The thermostable C1
variants were predicted by using two computational programs:
FireProt[23, 50] and FRESCO.[16, 51] The dimeric structure of C1 WT (PDB
ID: 5ZYR) was processed with the aid of the FireProt program,
which uses FoldX and Rosetta tools for calculation of the DDGfold
values that indicate folding stability. Only the C1 variants with
DDGfold values lower than @1 kcal mol@1 were selected for further
studies and analyses. The prediction with the aid of the FRESCO
program was performed along with energy-based calculation by
using the FoldX and Rosetta tools and prediction of disulfide bond
formation.[16]
Site-directed mutagenesis : The pET11a-C1 plasmid was used as a
template for site-directed mutagenesis to generate all C1 variants.
The PCR protocol was described in previous reports,[30, 33] and the
forward and reverse primers used for PCR reactions are shown in
Table S2. The PCR reaction mixture contained 1 V Pfu buffer with
MgSO4 (20 mm), each dNTP (0.4 mm), forward and reverse primers
(0.4 mm), Pfu DNA polymerase (2.5 U), and template (1 mg). The
PCR conditions were as follows: preheating of the reaction mixture
to 95 8C for 5 min, followed by 30 cycles of denaturation at 95 8C
for 30 s, annealing at 45–65 8C for 30 s, and elongation at 72 8C for
14 min. A final extension was carried out at 72 8C for 10 min. The
amplified products were analyzed on agarose gels (1 %), and the
Figure 5. Distances between A166/L166 and L168: A) in the wild type, and B) in the A166L variant over 6 ns MD simulation, at temperatures varying from
300–500 K. Interactions between A166/L166 of C) the wild type, and D) the A166L variant and other residues after 6-ns MD simulations.




expected product size was approximate 6.6 kbp. The template was
digested with DpnI (20 U) for 1 h at 37 8C (New England Biolabs).
Plasmids encoding for the C1 variants were propagated in E. coli
XL1-Blue and purified according to the FavorPrep Plasmid DNA
extraction Mini Kit protocols (Favorgen Biotech Corporation, Ping-
Tung, Taiwan). All plasmids were analyzed for their sequences at
1st BASE DNA Sequencing Services (Malaysia).
Protein expression and purification : The protocol for C1 enzyme
expression in E. coli BL21(DE3) was established and described in
previous reports.[30, 33] Protein purification was carried out according
to the previous protocol[29, 30, 33] with slight modifications. In brief,
the crude extract of each C1 enzyme was purified to homogeneity
by precipitation methods by using polyethylenimine (1 %, w/v) to
remove nucleic acid contents and ammonium sulfate (20–40 %, w/
v) to fractionate C1 enzyme, as well as anion-exchange chromatog-
raphy with a DEAE-Sepharose column at pH 7.0. The purified C1
enzyme was kept in MOPS buffer (pH 7.0, 100 mm) and stored at
@80 8C until use. The purity of each C1 enzyme was estimated by
SDS-PAGE analysis (12 %, w/v) and the amount of protein was
quantitated by use of the Bradford assay. The stock C1 enzyme
concentration was determined by using the molar absorption co-
efficient of bound FMN at 458 nm (e458 = 12.8 mm
@1 cm@1).
Measurement and kinetics of NADH oxidase activity : NADH ox-
idase activity of the C1 enzyme was measured by monitoring the
absorbance decrease at 340 nm with a Cary 100 UV/Vis spectro-
photometer (Agilent, USA). A typical assay reaction contained C1
(4–16 nm), FMN (15 mm), and NADH (200 mm) in sodium phosphate
buffer (pH 7.0, 50 mm) at 25 8C. Because C1 activity can be stimulat-
ed by HPA,[29–31, 33] the assay reactions were carried out in the pres-
ence of HPA for comparison with those performed in the absence
of HPA. Basal NADH oxidase activity was measured before the start
of the reaction by addition of HPA (200 mm). Therefore, the specific
NADH oxidation in the presence of C1 was calculated by subtract-
ing the basal NADH oxidase activity from the total NADH oxida-
tion. One unit of C1 activity is defined as the amount of enzyme re-
quired to oxidize 1 mmol of NADH per min under the assay condi-
tions. For NADH oxidase kinetics, various concentrations of NADH
(1–400 mm) were added to the triplicate assay reaction mixtures.
The initial rates (v) of the reactions were calculated and plotted
versus NADH concentrations. The curve plots were fitted by the
Michaelis–Menten equation [Eq. (1)] , in which vmax is the maximum
rate, Km is the Michaelis constant for substrate S, and S is the
[NADH], by using the Levenberg–Marquardt algorithm in Kaleida-
Graph version 4.0 software (Synergy Software) to determine the
kinetic parameters.
v ¼ vmaxS
K m þ S ð1Þ
Screening for thermostable C1 variants : A clear solution of a
crude extract of a C1 variant or WT was incubated in a water bath
heated at 45 8C for 10 min. After incubation, the pellet was separat-
ed by centrifugation. The protein content of the clear supernatant
Figure 6. Distances between A58/P58 and I14: A) in the wild type, and B) in the A58P variant over 6 ns MD simulation, at temperatures varying from 300–
500 K. The interactions between A58/P58 of C) the wild type, and D) the A58P variant and other residues after 6-ns MD simulations.




was determined by Bradford assay and the NADH oxidation activity
was measured by spectrophotometry as described above. The spe-
cific activity of each C1 variant was compared with that of the WT
enzyme. The C1 variants that had greater specific activity than the
WT were selected for further characterization.
Thermostability assay : Time-dependent thermal inactivation
assays of C1 enzymes were examined for evaluation of the enzyme
thermotolerance. Each C1 variant was incubated in a water bath
heated at 45 8C for various incubation times (0–180 min). At each
timepoint, an aliquot of C1 solution was taken and then added into
the assay reaction to measure NADH oxidation activity in the ab-
sence and in the presence of HPA as described earlier. The residual
activity of C1 at each timepoint was calculated and compared.
Thermal denaturation : A melting curve analysis of each C1 variant
was conducted to determine the thermal unfolding temperature
(Tm),
[65] by monitoring of the increase in the intrinsic fluorescence
of bound FMN upon thermal protein denaturation.[54] A C1 sample
(5 mm) was mixed with sodium phosphate buffer (pH 7.0, 50 mm)
in a total volume of 20 mL in a PCR tube. The intrinsic fluorescence
signal was monitored while the temperature was increased from
25 to 90 8C at a constant increment of 1 8C min@1 in an CFX96 real-
time PCR instrument (BIO-RAD, United Kingdom). The protein melt-
ing curve plot of intrinsic fluorescence signal versus temperature
was analyzed and used for determining the Tm value, the tempera-
ture at which half of the total protein is in the unfolded state.[66] Al-
ternatively, the melting curve plot can be transformed to the first
derivative plot of @dF/dT versus temperature [8C], in which the Tm
values correspond to peaks.[67]
Effect of temperature on transient kinetics of thermostable C1-
bound FMN reduction by NADH : Rate constants of flavin reduc-
tion at various temperatures were measured according to the pro-
cedure described previously.[68–71] In brief, the measurements were
performed with a TgK Scientific Model SF-61DX stopped-flow spec-
trophotometer in single-mixing mode. The stopped-flow apparatus
was made anaerobic by flushing the flow system with an oxygen
scrubbing solution containing glucose (20 mm) and glucose
oxidase (10 units). The oxygen scrubbing solution was allowed to
stand in the flow system overnight and the system was thoroughly
rinsed with the anaerobic buffer before experiments.
A solution (25 mm) of C1 WT or variant was mixed with NADH
(100 mm, concentrations after mixing) at various temperatures (15,
20, 25, 30, 35, 40, 45, and 50 8C) in a stopped-flow apparatus. The
absorbance changes at 458 nm were monitored. The apparent rate
constant of flavin reduction (kred) was calculated from the kinetic
traces by use of exponential fits and the software packages of
Kinetic Studio (TgK Scientific, Bradford-on-Avon, UK) or Program A
(developed by R. Chang, C.-J. Chiu, J. Dinverno, and D. P. Ballou, at
the University of Michigan, Ann Arbor, MI). The exponential curve
of kred versus temperatures was plotted and analyzed by use of the
Eyring equation [Eq. (2)] , in which kB is the Boltzmann constant
(1.381 V 10@23 J K@1), h is Planck’s constant (6.626 V 10@34 J s), T is the
absolute temperature, R is the gas constant (1.987 cal mol@1 K@1),
DH* is the enthalpy of activation, and DS* is the entropy of activa-
tion.[72] The linear form of the Eyring plot of ln(kred/T) versus 1/T
was analyzed by using Equation 3 to determine the enthalpy of























Measurement of in vitro bioluminescence by using thermosta-
ble C1 variants as electron donors for bacterial luciferase activi-
ty : A bacterial luciferase (luxAB) assay solution (100 mL) consisting
of FMN (10 mm), HPA (200 mm), NADH (200 mm), and decanal
(20 mm) in sodium phosphate buffer (pH 7.0, 50 mm) was freshly
prepared on ice and protected from light.[45] After all reagents had
been prepared, the luciferase assay solution was injected into a
mixture solution (10 mL) of luxAB (75 fm, 5 mL) and C1 (50 mU, 5 mL)
by using an AB-2270 luminometer (ATTO, Tokyo, Japan). The light
signal was integrated over 60 s and recorded at room temperature
(25 8C). It should be noted that C1 variants and WT were preheated
at 45 8C for 6 h or at 54 8C for 10 min prior to assay of the luxAB ac-
tivity. The bioluminescence signal obtained from the luxAB-cata-
lyzed reaction in the presence of the preheated C1 variants was
then compared with that obtained from the reaction in the pres-
ence of preheated or unheated WT.
Production of 3,4,5-THCA by using thermostable C1 variants for
generation of the reduced flavin : Previous reports showed that
the reaction catalyzed by C1 WT serves as a source of reduced
flavin for the C2-catalyzed bioconversion of p-coumaric acid (CMA)
to produce 3,4,5-THCA.[41, 42] Therefore, in this experiment, we inves-
tigated whether the selected thermostable C1 variants would ex-
hibit greater efficiency than the WT in producing the reduced
flavin for the C2-catalyzed reaction. The enzymatic cascade biocon-
version was carried out similarly to the previous protocols,[41, 42]
except that the NADH-regenerating system used in this experiment
was that based on Pseudomonas sp. 101 formate dehydrogenase
(PsFDH).[43, 44] This is because PsFDH has a rather high Tm value
[(66.7:0.5) 8C, data not shown]. It should be noted that C1 variants
and WT were preheated at 45 8C for 3 h prior to the bioconversion
reaction.
The reaction (10 mL) was carried out in sodium phosphate buffer
(pH 7.0, 100 mm) containing sodium formate (20 mm), preheated
C1 (0.1 mm), NAD
+ (400 mm), C2 Y398S variant (5 mm), FMN (1 mm),
CMA (50 mm), and ascorbic acid (1 mm), plus superoxide dismutase
(SOD, 50 unit mL@1). The reaction was initiated by addition of
PsFDH (1 mm) and performed at 25 8C. During the reaction prog-
ress, aliquots (100 mL) were taken at various times (0–2 h) and
quenched by addition of an equivalent volume of HCl (0.2 m). The
quenched solution was filtered with a Microcon ultrafiltration unit
(10 kDa cut-off, Millipore) to obtain the filtrate fraction containing
3,4,5-THCA, which was analyzed by HPLC (Agilent Technologies
1100 or 1260 Infinity series) equipped with a UV/visible diode-array
detector (DAD) and quadrupole mass spectrometric detector
(MSD). Liquid chromatographic (LC) separation was achieved with
a Nova-Pak C18 column (Waters Corporation, USA, 150 mm V
3.9 mm i.d. , 4 mm). Total run time for LC separation was 30 min
with a flow rate of 0.5 mL min@ 1. Solvents used for separation were
formic acid (0.1 %, v/v) in water (eluent A) and formic acid (0.1 %, v/
v) in methanol (eluent B). The separation protocol was as follows: a
linear gradient increasing from 0–25 % eluent B (t = 0–2 min), main-
tenance at 25 % eluent B (t = 2–10 min), a linear gradient increasing
from 25–50 % eluent B (t = 10–13 min), maintenance at 50 %
eluent B (t = 13–18 min), a linear gradient decreasing from 50–0 %
eluent B (t = 18–20 min). After each separation, the column was
equilibrated further for 10 min. A volume of 20 mL was injected for
all standard reagents and samples. The chromatographic peak with
the retention time at 4.6 min for 3,4,5-THCA product were detected
at 300 nm by the DAD and the corresponding 195 m/z was detect-
ed with the MSD. A standard curve of various known concentra-
tions of 3,4,5-THCA versus the corresponding peak areas was used
to quantitate concentration of the 3,4,5-THCA product formed at




each timepoint. The rate of 3,4,5-THCA product formation in the
reaction involving a preheated C1 variants was determined and
compared with that in the reaction involving preheated WT.
Effects of organic solvents on NADH oxidase activity of thermo-
stable C1 variants : The thermostable C1 variants and the WT were
pretreated with different concentrations (0, 10, 30 %, v/v) of differ-
ent types of organic solvents including DMSO, ethanol, and metha-
nol at 25 8C for 3 h. After incubation, the precipitated protein was
separated by centrifugation and the clear solution of C1 was used
for the assay as described earlier. The NADH oxidase activities of
the thermostable C1 variants treated with each solvent were com-
pared with those of the WT under the same conditions.
MD simulations : The C1 enzyme structure (PDB ID: 5ZYR) was ob-
tained from the Protein Data Bank (PDB). Hydrogen atoms of
amino acid residues were added by considering results from the
propka (http://propka.org).[73] The atom types in the topology files
were assigned with the aid of the CHARMM27 parameter set.[74]
The structure of the C1 enzyme was solvated in a cubic box of
TIP3P water extending at least 15 a in each direction from the
solute. The dimensions of the solvated system are 98 V 89 V 99 a.
MD simulations were carried out by using the NAMD program[75]
with simulation protocols adapted from our previous work[52] and
NAMD tutorials.[76, 77] The simulations were started by minimizing
hydrogen atom positions for 3000 steps followed by water minimi-
zation for 6000 steps. The system water was heated to 300 K for
5 ps and was then equilibrated for 15 ps. The whole system was
minimized for 10 000 steps and heated to 300 K for 20 ps. After
that, the whole system was equilibrated for 180 ps followed by
production stage for 6 ns. Molecular modeling of the WT and of
the A58P and A166L variants was investigated. To investigate tem-
perature effect on the enzyme stability, MD simulations were car-
ried out at 300–500 K. Some separations of important residues, as
represented by the distances between Ca atoms of the residue
pairs A58 and I14, A58 and F19, A166 and R201, and A166 and
Q204 were monitored during 6 ns MD simulations.
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